{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-026398","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.370358+00:00","generated_at":"2026-05-31T09:36:11.075909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyadic Q2 2024 revenue down 54% YoY to $386k; net loss $2.05M; cash $10.1M","bullets":["Net loss $2.045M ($0.07/share) vs $2.153M ($0.07) YoY; operating loss $2.043M.","Cash and securities $10.1M at June 30, 2024, up from $7.3M at Dec 31, 2023.","Partnered with Proliant Health for animal-free recombinant albumin; $500k initial payment received.","Joint development with a Top 10 global dairy for food-grade alpha-lactalbumin.","Avian flu H5 nanoparticle antigen shows high neutralizing antibody titers in animal studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-026398","json":"https://secwatch.observer/filing/0001437749-24-026398.json","markdown":"https://secwatch.observer/filing/0001437749-24-026398.md","text":"https://secwatch.observer/filing/0001437749-24-026398.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/0001437749-24-026398-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924026398/dyai20240523_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:36:11.075909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}